doi: 10.1159/000521264 Summary Keywords GLP-1R agonists, obesity, weight-reducing drugs, metabolic diseases, dual agonism Citation Wang J-Y, Wang Q-W, Yang X-Y, Yang W, Li D-R, Jin J-Y, Zhang H-C and Zhang X-F (2023) GLP1 receptor agonists for the treatment of obesity: Role as a promising approach
Studies suggest that physical activity can raise GLP-1 to levels that remain even after 24 hours have passed
avoid high-fat foods
Other common adverse effects include diarrhea, constipation, dyspepsia, abdominal pain, and decreased appetite [47]
When prescribed and monitored by a qualified healthcare provider, these medications can: Improve insulin sensitivity Reduce appetite and food cravings Support weight loss in certain patients However, outside of a controlled medical environmen t, these effects can become unpredictable and even dangerous
Novo was first to hit the jack pot with semaglutide, approved to treat diabetes in the UK in 2019 (as Ozempic)
